Core Viewpoint - The announcement details the conditional redemption of "Kehua Convertible Bonds" by Shanghai Kehua Bioengineering Co., Ltd, triggered by specific stock price conditions and outlines the redemption process and terms [1][2][6]. Redemption Conditions - The redemption price is set at 100.241 RMB per bond (including interest and tax) [1][6]. - The triggering date for the redemption conditions is September 5, 2025, when the stock price must be below 70% of the conversion price for 30 consecutive trading days [1][2][4]. Redemption Process - The redemption application period is from September 10 to September 16, 2025 [2][8]. - The funds will be credited to the issuer's account on September 19, 2025, with the redemption payment date set for September 22, 2025, and investors will receive the funds by September 23, 2025 [2][8]. Interest Calculation - The interest for the redemption is calculated based on a rate of 2.00% for the sixth interest period, resulting in an accrued interest of 0.241 RMB per bond [4][5][6]. Tax Implications - Individual investors will have a net redemption amount of 100.193 RMB per bond after a 20% tax deduction, while qualified foreign institutional investors (QFII and RQFII) are exempt from tax [6]. Trading and Conversion Restrictions - During the redemption application period, "Kehua Convertible Bonds" will continue to trade but will not allow conversion into shares [8].

Core Viewpoint - Kewah Bio announced that investors can choose to sell their "Kewah Convertible Bonds" at a price of 100.241 RMB per bond (including interest and tax) [2] Group 1 - The closing price of "Kewah Convertible Bonds" is currently higher than the repurchase price, indicating that investors opting for the repurchase may incur losses [2]

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2025-053 | 上海科华生物工程股份有限公司 关于"科华转债"回售的第三次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.241 元人民币/张（含息、税） 2、回售条件触发日：2025 年 9 月 5 日 3、回售申报期：2025 年 9 月 10 日至 2025 年 9 月 16 日 4、发行人资金到账日：2025 年 9 月 19 日 5、回售款划拨日：2025 年 9 月 22 日 6、投资者回售款到账日：2025 年 9 月 23 日 7、回售申报期内停止转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 10、风险提示：投资者选择回售等同于以 100.241 元人民币/张（含息、税） 卖出持有的"科华转债"。截至目前，"科华转债"的收盘价格高于 ...

Core Viewpoint - The company announces the conditional repurchase of its convertible bonds ("科华转债") due to the stock price falling below a specified threshold, allowing bondholders to sell their bonds back to the company at a predetermined price [2][3]. Summary of Key Points Repurchase Terms - The repurchase price is set at 100.241 RMB per bond, including interest and tax [1][7]. - The repurchase condition is triggered if the company's stock price falls below 70% of the conversion price (14.45 RMB) for 30 consecutive trading days [2][3]. - The repurchase period is from September 10, 2025, to September 16, 2025 [3][10]. Interest Calculation - The interest for the repurchase is calculated based on a formula that includes the bond's face value, the annual interest rate of 2.00%, and the number of days since the last interest payment [5][6]. - The calculated interest amounts to 0.241 RMB per bond, leading to a total repurchase price of 100.241 RMB [6][7]. Repurchase Rights - Bondholders have the option to sell back either part or all of their unconverted bonds, and the repurchase is not mandatory [8][9]. - If a bondholder does not submit a repurchase request during the specified period, they forfeit their right to do so for that interest year [10]. Repurchase Process and Payment - The company will announce the results of the repurchase and its impact after the repurchase period ends [11]. - Payments will be processed through the China Securities Depository and Clearing Corporation, with funds expected to be credited to investors by September 23, 2025 [11].

Core Points - Kewah Bio announced that investors can choose to sell their "Kewah Convertible Bonds" at a price of 100.241 RMB per bond, including interest and tax [2] - Currently, the closing price of "Kewah Convertible Bonds" is higher than the repurchase price, indicating that investors opting for the repurchase may incur losses [2]

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2025-052 | 上海科华生物工程股份有限公司 关于"科华转债"回售的第二次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.241 元人民币/张（含息、税） 2、回售条件触发日：2025 年 9 月 5 日 3、回售申报期：2025 年 9 月 10 日至 2025 年 9 月 16 日 4、发行人资金到账日：2025 年 9 月 19 日 5、回售款划拨日：2025 年 9 月 22 日 6、投资者回售款到账日：2025 年 9 月 23 日 1、回售条款 根据《募集说明书》，有条件回售条款的约定如下：在本次发行的可转债的 最后两个计息年度，如果公司股票在任何连续 30 个交易日的收盘价格低于当期 转股价格的 70%时，可转债持有人有权将其持有的可转债全部或部分按面值加当 期应计利息的价格回售给公司。若在上述交易日内发生过转股价格因发生送红股、 ...

Group 1 - The company, Kehua Bio-engineering, announced that as of the date of the announcement, neither the company nor its subsidiaries have provided guarantees to external entities that are not included in the consolidated financial statements [2] - There are no overdue guarantees reported by the company [2] - The company is not involved in any litigation related to guarantees, nor has it incurred losses due to being judged against in guarantee-related cases [2]

证券日报网讯 9月8日晚间，科华生物发布公告称，在回售款划拨日之前，如已申报回售的可转换公司 债券发生司法冻结或扣划等情形，债券持有人本次回售申报业务失效。风险提示：投资者选择回售等同 于以100.241元人民币/张（含息、税）卖出持有的"科华转债"。截至目前，"科华转债"的收盘价格高于 本次回售价格，投资者选择回售可能会带来损失，敬请广大投资者注意风险。 （文章来源：证券日报） ...

| 证券代码：002022 | 证券简称：科华生物 | | | --- | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2025-051 | 上海科华生物工程股份有限公司 关于"科华转债"回售的第一次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 7、回售申报期内停止转股 8、本次回售不具有强制性 9、在回售款划拨日之前，如已申报回售的可转换公司债券发生司法冻结或 扣划等情形，债券持有人本次回售申报业务失效。 10、风险提示：投资者选择回售等同于以 100.241 元人民币/张（含息、税） 卖出持有的"科华转债"。截至目前，"科华转债"的收盘价格高于本次回售价 格，投资者选择回售可能会带来损失，敬请广大投资者注意风险。 上海科华生物工程股份有限公司（以下简称"公司"）的股票自 2025 年 7 月 28 日至 2025 年 9 月 5 日连续 30 个交易日的收盘价格低于当期转股价 20.64 元/股的 70%（即 14.45 元/股），且"科华转债"处于最后两个计息年度。根据 《上海科华生 ...

| 证券代码：002022 | 证券简称：科华生物 | | --- | --- | | 债券代码：128124 | 债券简称：科华转债 | 公告编号：2025-050 上海科华生物工程股份有限公司 关于为子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 上海科华生物工程股份有限公司（以下简称"公司"）于 2025 年 2 月 10 日 召开第十届董事会第十一次会议，审议通过了《关于 2025 年度向金融机构融资 和为子公司提供担保的议案》，公司及全资、控股子公司（均为合并报表范围内 的子公司，以下统称"子公司"）拟向金融机构申请不超过人民币 100,000 万元(含 本数)的融资额度及人民币 80,000 万元（含本数）的并购和项目贷款融资额度， 并为子公司提供担保总额不超过人民币 20,000 万元（含本数）的连带责任担保。 具体详见公司于 2025 年 2 月 11 日在《证券时报》、《中国证券报》、《上海证券报》 和巨潮资讯网（http://www.cninfo.com.cn）披露的《关于 2025 年度向金融机 构 ...